Even though PCa is still trailing other cancers in biomarker guided treatment, genes such as PTEN, ERG, AR and TP53 have been noted as clinically relevant biomarkers to predict patient’s outcomes and suggest therapeutic strategies [4,31]. This evidence concerns the gene PTEN and posterior cortical atrophy.